Haematologists can have confidence in the equivalence of biosimilar products to the original reference molecule when it comes to efficacy, safety and when switching between products, a new Australian consensus statement advises. With the emergence of biosimilar brands for biologic agents used in haematology such as rituximab, clinicians and patients need to be informed and ...
Have confidence in biosimilars in haematology: consensus statement
By Michael Woodhead
15 Apr 2020